Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

Vincent Chouraki; Alexa Beiser; Linda Younkin; Sarah Rosner Preis; Galit Weinstein; Oskar Hansson; Ingmar Skoog; Jean Charles Lambert; Rhoda Au; Lenore Launer; Philip A. Wolf; Steven Younkin; Sudha Seshadri

doi:10.1016/j.jalz.2014.07.001

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

Vincent Chouraki, Alexa Beiser, Linda Younkin, Sarah Rosner Preis, Galit Weinstein, Oskar Hansson, Ingmar Skoog, Jean Charles Lambert, Rhoda Au, Lenore Launer, Philip A. Wolf, Steven Younkin, Sudha Seshadri

Research output: Contribution to journal › Article › peer-review

Abstract

Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ_1-42 and Aβ_1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ_1-42 levels were associated with lower risk of dementia (Aβ_1-42: hazard ratio [HR] = 0.80 [0.71â€ 0.90], P <.001; Aβ_1-42-to-Aβ_1-40 ratio: HR = 0.86 [0.76â€ 0.98], P =.027) and AD (Aβ_1-42: HR = 0.79 [0.69â€ 0.90], P <.001; Aβ_1-42-to-Aβ_1-40 ratio: HR = 0.83 [0.72â€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

Original language	English
Pages (from-to)	249-257.e1
Journal	Alzheimer's and Dementia
Volume	11
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2014.07.001
State	Published - 1 Mar 2015
Externally published	Yes

Bibliographical note

Publisher Copyright:
© 2015 The Alzheimer's Association.

Keywords

Alzheimer's disease
Aβ peptides
Epidemiology
Framingham
Heart
Incident
Incident dementia
Meta-analysis
Plasma biomarker
Study

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2014.07.001

Cite this

@article{be078b276b3344a2b2e117152768c7cb,

title = "Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study",

abstract = "Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76{\^a}€ 0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69{\^a}€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72{\^a}€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.",

keywords = "Alzheimer's disease, Aβ peptides, Epidemiology, Framingham, Heart, Incident, Incident dementia, Meta-analysis, Plasma biomarker, Study",

author = "Vincent Chouraki and Alexa Beiser and Linda Younkin and Preis, {Sarah Rosner} and Galit Weinstein and Oskar Hansson and Ingmar Skoog and Lambert, {Jean Charles} and Rhoda Au and Lenore Launer and Wolf, {Philip A.} and Steven Younkin and Sudha Seshadri",

note = "Publisher Copyright: {\textcopyright} 2015 The Alzheimer's Association.",

year = "2015",

month = mar,

day = "1",

doi = "10.1016/j.jalz.2014.07.001",

language = "English",

volume = "11",

pages = "249--257.e1",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

AU - Chouraki, Vincent

AU - Beiser, Alexa

AU - Younkin, Linda

AU - Preis, Sarah Rosner

AU - Weinstein, Galit

AU - Hansson, Oskar

AU - Skoog, Ingmar

AU - Lambert, Jean Charles

AU - Au, Rhoda

AU - Launer, Lenore

AU - Wolf, Philip A.

AU - Younkin, Steven

AU - Seshadri, Sudha

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71â€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76â€ 0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69â€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72â€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

AB - Background Plasma amyloid-β (Aβ) peptide levels have been examined as a low-cost accessible marker for risk of incident Alzheimer's disease (AD) and dementia, but results have varied between studies. We reassessed these associations in one of the largest, prospective, community-based studies to date. Methods A total of 2189 dementia-free, Framingham Study participants aged >60 years (mean age, 72 ± 8 years; 56% women) had plasma Aβ1-42 and Aβ1-40 measured and were followed prospectively (mean, 7.6 ± 3.0 years) for dementia/AD. Results Increased plasma Aβ1-42 levels were associated with lower risk of dementia (Aβ1-42: hazard ratio [HR] = 0.80 [0.71â€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.86 [0.76â€ 0.98], P =.027) and AD (Aβ1-42: HR = 0.79 [0.69â€ 0.90], P <.001; Aβ1-42-to-Aβ1-40 ratio: HR = 0.83 [0.72â€ 0.96], P =.012). Conclusion Our results suggest that lower plasma Aβ levels are associated with risk of incident AD and dementia. They encourage further evaluation of plasma Aβ levels as a biomarker for risk of developing clinical AD and dementia.

KW - Alzheimer's disease

KW - Aβ peptides

KW - Epidemiology

KW - Framingham

KW - Heart

KW - Incident

KW - Incident dementia

KW - Meta-analysis

KW - Plasma biomarker

KW - Study

UR - http://www.scopus.com/inward/record.url?scp=84925961850&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2014.07.001

DO - 10.1016/j.jalz.2014.07.001

M3 - Article

C2 - 25217292

AN - SCOPUS:84925961850

SN - 1552-5260

VL - 11

SP - 249-257.e1

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

IS - 3

ER -

Plasma amyloid-β and risk of Alzheimer's disease in the Framingham Heart Study

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this